[0:00–0:19]
On-Screen Title: Neoadjuvant immunotherapy and radiation boosts response in NSCLC
Dr. Nasser Altorki: Hello, my name is Nasser Altorki and I’m the chief of Thoracic Surgery at the NewYork-Presbyterian Hospital Weill Cornell Medicine. I’m also the leader of the Experimental Therapeutics Program at the Meyer Cancer Center of Weill Cornell Medicine.
[0:20–0:45]
Dr. Nasser Altorki: The focus of our program is the clinical trials in patients with early-stage lung cancer, especially clinical trials that introduce new options for patients with that stage of disease. One of the trials that we conducted recently is a trial looking at the role of low-dose radiation, which is delivered over a short period of time, really 3 days, combined with immunotherapy.
On-Screen Title: Exploring chemo-free treatment options
[0:46–1:24]
Dr. Nasser Altorki: It was, to our knowledge, the first in-human trial that used low-dose radiation combined with immunotherapy. More patients in the combined modality arm had more than 90% of the cancer cells eliminated and some actually had no cancer cells found in the specimen that we removed at the time of surgery. And this is what it’s all about, more options for patients that provide them with excellent outcomes.
On-Screen Title: 90% cancer cells eliminated
On-Screen Title: A Phase II trial is underway comparing this dual therapy to neoadjuvant chemotherapy, the standard of care
[END]
